文献速递脊柱关节炎

司库奇尤单抗剂量递增研究:强直性脊柱炎患者治疗16周未达非活动性疾病后的疗效

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

ASLeap试验(NCT03350815)为随机、双盲、平行组、多中心4期研究,强直性脊柱炎患者接受开放标签司库奇尤单抗150 mg治疗16周后,第12周和第16周均未达ASDAS<1.3者按1:1随机接受300 mg或150 mg每4周至第52周。第52周300 mg组8.8%、150 mg组6.7%达ASDAS<1.3,两组不良事件发生率相似,未见新安全信号。

要点

  • 322例接受司库奇尤单抗150 mg治疗的患者中207例(64.3%)为应答不足。
  • 第52周ASDAS<1.3达成率:300 mg组8.8% vs 150 mg组6.7%。
  • 两组至第52周治疗中出现的不良事件发生率相似,未见新安全信号。

核心结论

  • 强直性脊柱炎患者接受司库奇尤单抗150 mg治疗16周未达ASDAS<1.3后,剂量递增至300 mg与继续150 mg相比,至第52周临床应答和安全性相似。

研究设计与样本

  • ASLeap(NCT03350815)为随机、双盲、平行组、多中心4期试验。
  • 患者先接受开放标签司库奇尤单抗150 mg治疗16周(治疗期1)。
  • 第12周和第16周均未达ASDAS<1.3者判定为应答不足,按1:1随机接受司库奇尤单抗300 mg或150 mg每4周至第52周(治疗期2)。
  • 主要疗效变量为以第16周为基线、第52周达到ASDAS<1.3。
  • 安全性通过至第52周治疗中出现的不良事件(TEAEs)发生率评估。

主要发现

  • 治疗期1接受司库奇尤单抗治疗的322例患者中,207例(64.3%)为应答不足。
  • 应答不足者随机至300 mg组(n=101)和150 mg组(n=105),完成研究比例分别为83.8%和84.3%。
  • 第52周达到ASDAS<1.3的患者比例:300 mg组8.8% vs 150 mg组6.7%。
  • 至第52周两组TEAEs发生率相似,未见新安全信号。

关键数值与推荐

  • 非活动性疾病定义为ASDAS<1.3。
  • 应答不足定义为第12周和第16周均未达ASDAS<1.3。
  • 主要疗效变量为第52周达到ASDAS<1.3(以第16周为基线)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical response at week 52 in patients with AS who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week 16. METHODS: ASLeap (NCT03350815) was a randomized, double-blind, parallel-group, multicentre, phase 4 trial. After 16 weeks of open-label secukinumab 150 mg (Treatment Period 1), patients who did not achieve inactive disease [AS Disease Activity Score (ASDAS) <1.3] at both week 12 and 16 were considered to have an inadequate response and were randomized 1:1 to receive secukinumab 300 or 150 mg every 4 weeks until week 52 (Treatment Period 2). The primary efficacy variable was achievement of ASDAS <1.3 at week 52 using week 16 as baseline. Safety was evaluated by the incidence of treatment-emergent adverse events (TEAEs) through week 52. RESULTS: Of 322 patients treated with secukinumab in Treatment Period 1, 207 (64.3%) had inadequate response. Similar proportions of patients with inadequate response randomized to secukinumab 300 mg (n = 101) and 150 mg (n = 105) in Treatment Period 2 completed the study (83.8% and 84.3%, respectively). At week 52, 8.8% and 6.7% of patients receiving secukinumab 300 and 150 mg, respectively, achieved ASDAS <1.3. The incidence of TEAEs was similar in both groups through week 52. No new safety signals were observed. CONCLUSION: Patients with AS who did not achieve ASDAS <1.3 after receiving secukinumab 150 mg for 16 weeks experienced similar clinical response and safety through week 52 regardless of dose escalation. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03350815.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Deodhar A, Kivitz AJ, Magrey M, et al. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). 2025. PMID: 39133200. doi:10.1093/rheumatology/keae432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。